BioSpace News Archive

BioArctic AB’s partner Eisai will hold several presentations at the Alzheimer’s Association International Conference to be held in Denver, Colorado and virtually from July 26 to 30, 2021.

Calliditas Therapeutics AB, and STADA Arzneimittel AG announced that they have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy in the European Economic Area member states, Switzerland and the UK.

The shareholders of Elekta AB, reg. no 556170-4015 are hereby convened to the Annual General Meeting to be held on Wednesday 25 August 2021.

Kurin Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture collection sets, announced that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference.

Ascentage Pharma, a globally focused biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration recently granted an Orphan Drug Designation to the company’s MDM2-p53 inhibitor, APG-115, for the treatment of stage IIB-IV melanoma.

Johnson & Johnson announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer.

Bruker Corporation announced it will report second quarter 2021 financial results on Monday, August 2, 2021, after the market closes.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.

Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, announced the closing of a $68 million Series D financing and provided a pipeline update.

Codex DNA, Inc. today announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), for its industry-leading CleanCap® technology.